Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 191 clinical trials
Featured trial
Pancreatic Adenocarcinoma - Advanced

Pancreatic Adenocarcinoma - Advanced

  • 225 views
  • 08 Nov, 2020
  • 1 location
Featured trial
RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

  • 634 views
  • 08 Nov, 2020
  • 1 location
Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology

Using gemcitabine and nab-paclitaxel, the investigators hope to establish the differential ability of local and cytologically positive disease to respond to this regimen, and in particular, the frequency of cytologic conversion from positive to negative in such patients. The investigators also can begin to assess the value of maximum local …

pdac
platelet count
gemcitabine
ductal adenocarcinoma
paclitaxel
  • 2 views
  • 15 Feb, 2022
  • 1 location
Neoadjuvant GMCI Plus Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma (PaTK02)

The purpose of this study is to evaluate Gene Mediated Cytotoxic Immunotherapy (GMCI) in combination with standard of care chemoradiation and surgery for borderline resectable and unresectable locally advanced pancreatic cancer in patients who have completed induction chemotherapy. GMCI kills tumor cells and creates an immune stimulatory environment in the …

cancer
metastatic pancreatic adenocarcinoma
tumor cells
neutrophil count
  • 0 views
  • 25 Jan, 2022
  • 4 locations
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

This study is a two stage study consisting of a dose escalation phase Ib and a phase II study which include subjects with previously-treated, advanced pancreatic adenocarcinoma. Dose Limiting

  • 0 views
  • 23 Mar, 2022
  • 1 location
1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

Assess the effectiveness of galeterone in advanced pancreatic adenocarcinoma

  • 4 views
  • 21 Feb, 2022
  • 1 location
Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma (CA209-9KH)

Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma

  • 2 views
  • 24 Feb, 2022
  • 3 locations
A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma

Within the next decade, pancreatic ductal adenocarcinoma (PDAC) is expected to rise to the second leading cause of cancer-related mortality. To increase the survival, various peri-operative treatments have been tested, and adjuvant FOLFIRINOX or gemcitabine plus capecitabine is now standard of care after surgical resection for localized PDAC. Even with …

  • 0 views
  • 10 Oct, 2021
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

To determine the rate of disease control of the combination of 9-ING-41 and retifanlimab plus gemcitabine/nab-paclitaxel in patients with pancreatic cancer without prior systemic therapy for advanced disease. The researchers will be looking at how the cancer you have reacts to the addition of 9-ING-41 and retifanlimab to the standard …

  • 0 views
  • 23 Mar, 2022
  • 1 location
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

, recurrent, or metastatic pancreatic adenocarcinoma as first line therapy. The phase 1b portion of the study is open label and patients will receive AVB-S6-500, nab-paclitaxel, and gemcitabine. The Phase 2

  • 0 views
  • 12 Mar, 2022
  • 10 locations